Vistagen Therapeutics, Inc. 8-K

What Happened
Vistagen Therapeutics, Inc. announced on May 12, 2026 (via a press release attached to a Form 8‑K) that it has observed preliminary positive results from the ongoing open‑label extension portion of its PALISADE‑3 Phase 3 study of fasedienol for the acute treatment of social anxiety disorder (SAD). The company filed the 8‑K under Item 8.01 (Other Events) and attached the press release as Exhibit 99.1.

Key Details

• Date filed: May 12, 2026 (Form 8‑K, Item 8.01).
• Study: PALISADE‑3 Phase 3, open‑label extension evaluating fasedienol for acute treatment of social anxiety disorder.
• Data status: Described as "preliminary positive" from the ongoing open‑label extension (not final or from the blinded randomized portion).
• Filing details: Press release attached as Exhibit 99.1; Form 8‑K signed by CEO Shawn K. Singh.

Why It Matters
Positive preliminary data in a Phase 3 program signals clinical progress for fasedienol and may influence investor interest, partnerships, or future regulatory steps. However, these are interim/open‑label results; investors should note they are not the final randomized, controlled outcomes. Monitor follow‑up announcements for full data, statistical details, and any regulatory or development updates.